RxDoctor Payments Data

Omofolarin Arthur, DO

Family Medicine · Warren, MINPI 1104315688

Payments from drug & device makers

$1,207in general payments, 2019–2025

Across 52 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$637
  • Tactile Systems Technology Inc$170
  • Merck$79
  • Boston Scientific$57
  • Amgen$53
  • Daiichi Sankyo Inc.$37
  • plus $174 from 10 others

What the payments were for

  • Food & beverage$1,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$39,978
Medicare patients
214
Services billed
1,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$59,415
JardianceEmpagliflozin32$35,909
JanuviaSitagliptin Phosphate39$28,567
RybelsusSemaglutide16$18,391
MounjaroTirzepatide13$13,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,329
JanumetSitagliptin Phos/Metformin Hcl11$8,200
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,877
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,302
Gabapentin115$2,298
Atorvastatin Calcium258$1,974
Omeprazole136$1,917
Isosorbide Dinitrate12$1,637
Metoprolol Succinate101$1,377
Levothyroxine Sodium138$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$637$77,80652 claims
MerckJanuvia, Janumet$79$36,76750 claims
Boehringer IngelheimJardiance$19$35,90932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →